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High-throughput screening for fatty acid uptake inhibitors
in humanized yeast identifies atypical antipsychotic
drugs that cause dyslipidemias
Hong Li, Paul N. Black, Aalap Chokshi, Angel Sandoval-Alvarez, Ravi Vatsyayan, Whitney Sealls,
and Concetta C. DiRusso1
Center for Metabolic Disease, Ordway Research Institute, Inc., and Center for Cardiovascular Sciences,
Albany Medical College, Albany, NY 12208

Abstract Fatty acids are implicated in the development of
dyslipidemias, leading to type 2 diabetes and cardiovascular disease. We used a standardized small compound library
to screen humanized yeast to identify compounds that inhibit fatty acid transport protein (FATP)-mediated fatty acid
uptake into cells. This screening procedure used live yeast
cells expressing human FATP2 to identify small compounds
that reduced the import of a fluorescent fatty acid analog,
4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid (C1-BODIPY-C12). The library used consisted of
2,080 compounds with known biological activities. Of these,
?1.8% reduced cell-associated C1-BODIPY-C12 fluorescence
and were selected as potential inhibitors of human FATP2mediated fatty acid uptake. Based on secondary screens, 28
compounds were selected as potential fatty acid uptake inhibitors. Some compounds fell into four groups with similar structural features. The largest group was structurally
related to a family of tricyclic, phenothiazine-derived drugs
used to treat schizophrenia and related psychiatric disorders, which are also known to cause metabolic side effects,
including hypertriglyceridemia. Potential hit compounds were
studied for specificity of interaction with human FATP and
efficacy in human Caco-2 cells. This study validates this
screening system as useful to assess the impact of drugs in
preclinical screening for fatty acid uptake.—Li, H., P. N.
Black, A. Chokshi, A. Sandoval-Alvarez, R. Vatsyayan, W.
Sealls, and C. C. DiRusso. High-throughput screening for
fatty acid uptake inhibitors in humanized yeast identifies
atypical antipsychotic drugs that cause dyslipidemias. J. Lipid
Res. 2008. 49: 230–244.
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During the past 20 years, obesity among adults and
children has increased significantly in the United States.
Being overweight or obese increases the risk for the development of adverse health conditions, including hyperManuscript received 14 June 2007 and in revised form 7 August 2007 and in
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tension, dyslipidemia, diabetes, cardiovascular disease, and
certain types of cancer, particularly colon and breast (1–6).
It is hypothesized that high circulating levels of free fatty
acids, occurring as a result of various metabolic disturbances, including overeating and diabetes, lead to excessive fatty acid internalization. Cell death results when the
accumulation of these free fatty acids, especially saturated
fatty acids, exceeds the cell’s capacity for triglyceride storage, resulting in high levels of fatty acid oxidation, oxidative
stress, and ceramide production (7, 8). This is termed lipotoxicity and is correlated with the development of obesity,
insulin resistance, and cardiovascular disease (9–12). Therefore, it is desirable to target factors that contribute to fatty
acid internalization and accumulation to prevent lipotoxicity.
Several lines of evidence favor the involvement of proteins in the import of exogenous fatty acids. First, fatty
acid transport into cells is regulated by insulin, and emerging evidence shows that key transcriptional regulators,
including peroxisome proliferator-activated receptor a,
sterol-regulatory element binding protein 1, and retinoid X
receptor, participate in these regulatory processes (13–16).
Second, cells with high levels of fatty acid metabolism
(either degradation or storage) transport fatty acids at
higher rates compared with those with low levels of fatty
acid metabolism (17, 18). Third, fatty acid transport is inducible in several different cell types and is commensurate
with the expression of specific sets of proteins that are
likely to participate in this process (19–21). Among these
are the fatty acid transport proteins (FATPs) and long-

Abbreviations: ACSL, long-chain acyl-coenzyme A synthetase; AFU,
arbitrary fluorescence unit; C1-BODIPY-C12, 4,4-difluoro-5-methyl-4-bora3a,4a-diaza-s-indacene-3-dodecanoic acid; FAF BSA, fatty acid-free bovineserum albumin; FATP, fatty acid transport protein; HTS, high-throughput
screening; Ki, inhibition constant; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide; OD600, optical density at 600 nm; YNBD,
yeast minimal medium with dextrose; YPDA, yeast complete media
with adenine.
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chain acyl-coenzyme A synthetases (ACSLs) (22–24). The
involvement of both FATP and ACSL is consistent with
the model of vectorial acylation, in which fatty acid uptake is coupled to esterification with CoA (25–28). Our
own work exploiting the genetically tractable yeast Saccharomyces cerevisiae has demonstrated that a membranebound FATP homolog, Fat1p, and an ACSL, either Faa1p
or Faa4p, interact physically as well as functionally to catalyze import and activation (reviewed in Ref. 29). Fat1p
and ACSL are both essential when cells are grown under
hypoxic conditions, which render yeast auxotrophic for
long-chain unsaturated fatty acids (30). Likewise, specific
interactions have also been demonstrated between FATP1
and ACSL1 to potentiate fatty acid uptake in murine adipocytes (28). A number of studies have shown that fatty
acid transport, particularly for protonated fatty acids, may
also occur by diffusion or flip-flop between the two faces
of the membrane (31–37). Using adipocytes, it was demonstrated that the association and flip-flop of oleate across
the plasma membrane occurred very rapidly (33). A recent
review of the diffusional model of fatty acid transport
suggests that flip-flop is tied to the metabolic conversion to
acyl-CoA, consistent with our model of vectorial acylation
(32). Together, these reports provide compelling evidence
for targeting fatty acid transport to limit the cellular uptake
of fatty acids and thus lipotoxicity.
Previously, we developed a live cell high-throughput
screening (HTS) assay using a fat1Dfaa1D yeast strain to
identify chemical compounds that will inhibit fatty acid
uptake (P. N. Black and C. C. DiRusso, United States Patent
7,070,944) (38). In this system, transport is a function of
mouse FATP2 expressed from a yeast promoter and longchain fatty acid activation is provided by the endogenous
ACSL Faa4p. We demonstrated that this HTS assay is
rapid to execute, inexpensive to implement, and has appropriate sensitivity for HTS. In the present work, we
conducted a pilot study using a 2,080 compound library
from MicroSource Discovery Systems, Inc. (Gaylordsville,
CT), called SpectrumPlus: to improve and validate this
live cell HTS method. We also devised secondary screens
to eliminate false-positives in the yeast system and further evaluated the potential hit compounds using the human Caco-2 cell line. The members of the largest family
of structurally related compounds identified in this
screen are derivatives of a tricyclic phenothiazine core
from which atypical antipsychotic drugs have been developed. Among these are chlorpromazine and the related compound clozapine. Many of the drugs in this class
cause adverse side effects, including weight gain, hypertriglyceridemia, hyperglycemia, and ketoacidosis, which in
severe cases have led to patient death (reviewed in Ref. 39).
Consequently, several of these drugs have received black
box warning labels. The mechanism by which these drugs
cause these clinical symptoms is unknown. Our identification of these compounds as inhibitors of fatty acid uptake leads us to suggest that the metabolic dysregulation
associated with the administration of these drugs is caused
in whole or in part by reduced fatty acid uptake, resulting
in the disruption of normal cellular lipid trafficking.

MATERIALS AND METHODS
Chemical compound library
The SpectrumPlus compound library (2,080 compounds) was
obtained from MicroSource Discovery Systems, Inc. The library
includes five subsets of compounds: 1) Genesis Plus, composed
of 960 compounds that represent new and classical therapeutic
agents as well as established experimental inhibitors and receptor agonists; 2) Pure Natural Products Collection, a unique
collection of 720 diversified pure natural products and their
derivatives, including simple and complex oxygen heterocycles,
alkaloids, sequiterpenes, diterpenes, pentercyclic triterpenes, sterols, and many other diverse representatives; 3) Agro Plate, containing 80 compounds representing classical and experimental
pesticides, herbicides, and purported endocrine disruptors;
4) Cancer Plate, including 80 cytotoxic agents, antiproliferative agents, immune suppressants, and other experimental and
therapeutic agents; and 5) Spectrum Plus Plate, containing
240 biologically active and structurally diverse compounds. The
compounds are supplied as 10 mM solutions in DMSO and
were diluted in PBS to a final concentration of 80 mM for
screening in yeast using a Caliper RapidPlate 96/384 Dispenser
(Caliper Life Sciences, Hopkinton, MA).

Reagents and cell culture
Yeast extract, yeast peptone, and yeast nitrogen base without
amino acids and dextrose were obtained from Difco (Detroit,
MI). Complete amino acid supplement and single amino acids
were from Sigma (St. Louis, MO). Fatty acid-free bovine serum
albumin (FAF BSA) and other chemical reagents were also from
Sigma, unless stated otherwise. Corning: white with clear flatbottom 96-well and 384-well microplates were used for screening
of yeast. For Caco-2 cells, tissue culture-treated 96-well transparent with clear flat-bottom polystyrene microplates were from
Fisher Scientific (Pittsburgh, PA). The fluorescent long-chain fatty
acid analog, 4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3dodecanoic acid (C1-BODIPY-C12), was obtained from the Molecular Probes Division of Invitrogen.
S. cerevisiae strain LS2086 containing deletions within the FAT1
and FAA1 genes (fat1Dfaa1D; MATa ura3-52 his3D200 ade2-101
lys2-801 leu2-3,112 faa1::HIS3 fat1D::G418) (26) was used for the
primary screen. For most experiments, yeast minimal medium
with dextrose (YNBD) contained 0.67% yeast nitrogen base (YNB),
2% dextrose, adenine (20 mg/l), uracil (20 mg/l), and amino acids
as required [arginine, tryptophan, methionine, histidine, and tyrosine (20 mg/l); lysine (30 mg/l); and leucine (100 mg/l)]. When
a rich medium was required (e.g., toxicity studies in yeast), yeast
complete media with adenine (YPDA) was used. Growth in liquid
culture and on plates was at 30jC.
Caco-2 cells were maintained in Earl’s minimal essential
medium with 20% FBS in a 95% air/5% CO2 atmosphere at
37jC, as described previously (40). For growth and differentiation, the BD Biosciences Intestinal Epithelium Differentiation
Media Pack was used. Cells were plated in basal seeding medium
at a density of 2.5 3 105 cells/cm2 on a collagen-coated blackclear 96-well plate (BD Biosciences). Entero-STIM medium was
added to each well after removal of the basal seeding medium
24 h later. Both media contained mito-serum extender. After
another 24 h, cells were washed once with complete balanced
Hanks’ solution containing Ca21 and Mg21 without phenol red
before the C1-BODIPY-C12 uptake assay.

Cloning and expression of human FATP2 in yeast
For expression of the human FATP2 in yeast, the cDNA encoding the protein was amplified using PCR from a cDNA within
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NIH Image Clone I.D. 30348317 using forward primer 5¶-gcatagccctcgagatgctttccgccatctacaca-3¶ and reverse primer 5¶-cgcagaccaagctttcagagtttcagggtttttagc-3¶. The amplified DNA was cloned
into the yeast expression vector pDB121 to give pDB126. In this
construct, the expression of targeted human FATP2 is under
the control of the GAL10 promoter (41). The human FATP2
plasmid and pRS416GAL4-ER-VP16 encoding a synthetic transcriptional activator, which is a protein fusion between the Gal4
DNA binding domain, a b-estradiol-responsive regulatory domain, and a VP16 RNA polymerase activation domain (42), were
cotransformed into strain LS2086 for HTS assays. Expression of
human FATP was induced by the growth of yeast cells overnight in selective medium containing 10 nM b-estradiol. The
level of human FATP2 protein was routinely measured using
an antibody directed toward a T7 epitope fused to the C terminus of human FATP2 in Western blots of cell extracts.

HTS
For screening of the 2,080 compound MicroSource library, a
Biomek: FX laboratory automated workstation (Beckman Coulter,
Inc., Fullerton, CA) was used. LS2086 yeast cells expressing human FATP2 (pDB126/fat1Dfaa1D) or transformed with the empty
vector pDB121 (negative control cells) were pregrown in YNBD
without leucine and uracil (YNBD 2leu 2ura); the cells were subsequently subcultured to absorbance at 600 nm 5 0.02 in the same
medium containing 10 nM b-estradiol to induce expression and
incubated overnight at 30jC with shaking. Mid-log-phase yeast cells
[0.8–1.2 optical density at 600 nm (OD600)] were harvested and
resuspended in PBS at a cell density of 6 3 107/ml before dispensing to a 384-well assay plate (22.5 ml/well). Wells in the first
two rows of each plate received the negative control cells, and all
other wells received cells expressing human FATP2. Compounds
(2.5 ml) were then added to a final concentration of 80 mM. After
2 h of incubation at 30jC, the C1-BODIPY-C12 uptake assay was
performed. To each well, a mixture of C1-BODIPY-C12 (final concentration, 1.25 mM), FAF BSA (final concentration, 0.75 mM), and
trypan blue (final concentration, 2.1 mM) was added to give a final
volume of 100 ml. Trypan blue quenched the extracellular fluorescence, and only cell-associated fluorescence was measured
after 30 min on a Bio-Tek Synergy HT multidetection microplate
reader (Bio-Tek Instruments, Inc., Winooski, VT) with filter sets
of 485 6 20 nm excitation and 528 6 20 nm emission. On each
plate, two rows each of negative control cells and positive control
cells were incubated with 0.8% DMSO in PBS and assayed simultaneously to calculate a Z¶ factor for each plate. The results
presented are the values obtained for two screening experiments
(see Tables 1, 3–7 below).

Determination of inhibition constant
Ligand competition curves were fit by nonlinear least-squares
regression using a one-site competition model and Prism software (GraphPad Software, Inc., San Diego, CA) to determine the
concentration of added competitor that reduced C1-BODIPY-C12
fluorescence readout by 50% (IC50). Inhibition constant (Ki)
values were calculated from the IC50 by the equation of Cheng
and Prusoff (43): Ki 5 IC50/(1 1 [radioligand]/Kd), where
radioligand is the concentration of C1-BODIPY-C12 and Kd is the
apparent affinity of C1-BODIPY-C12 for the yeast cells expressing human FATP2 or Caco-2 cells. The apparent Kd was determined by measuring uptake activity in the presence of different
C1-BODIPY-C12 concentrations.

Toxicity assays
Wild-type yeast strain YB332 was used to evaluate the compound toxicity. Cells were grown in YPDA overnight and sub-
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cultured into the same medium at 0.1 OD600 in the presence
of different concentrations of compound as indicated. Optical
density was measured every hour during 8 h of growth. To test
viability after treatment, cells were grown and treated with compound for 2 h as usual to test uptake inhibition but were harvested by centrifugation, washed three times with PBS, serially
diluted, and plated on YPDA. After growth for 2 days at 30jC,
colony numbers were counted and scored to give the number
of colony-forming units per milliliter.
To evaluate potential toxic effects on Caco-2 cells, we used the
MTT [for 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] assay (44). For these experiments, cells were treated
with compound exactly as in the uptake assay using a 96-well format. At the end of the incubation period with test compound,
the medium was removed and cells were treated with 100 ml of
MEM containing 1.2 mM MTT for 3 h at 37jC. The reaction
was terminated and cells were lysed by the addition of 5% SDS
and 0.005 N HCl with incubation at 37jC for 1 h. The final absorbance was read at 570 nm to detect the formation of the purple
formazan product. Cell viability was determined relative to a standard curve prepared using untreated cells.

Lipid analyses
To identify lipids labeled with C1-BODIPY-C12, LS2086 yeast
cells (pDB126/fat1Dfaa1D) were grown in 50 ml of YNBD (2leu,
2ura) containing 10 nM b-estradiol to 1.0 OD600 at 30jC. The
culture was then concentrated by centrifugation and resuspended in PBS to a cell density of 6 3 107/ml. To half of the
cell suspension, perphenazine (in PBS) was added to a final
concentration of 40 mM; a control flask received PBS alone.
Incubation with the compound continued for 2 h, then C1BODIPY-C12 (final concentration, 1.25 mM) in FAF BSA (final
concentration, 0.75 mM) was added for 30 min to evaluate uptake. Metabolism was stopped by the addition of 0.1 volume of
6.6 M perchloric acid. Lipids were extracted essentially as detailed previously (45). After extraction, the dried lipids were
resuspended in 50 ml of chloroform, and aliquots (5 ml) were
spotted to Whatman Partisil LK5 TLC plates (250 mm, 150 Å
silica). To resolve phospholipids, the solvent was a mixture of
25 ml of methyl acetate, 25 ml of 2-propanol, 28 ml of chloroform, and 7 ml of 0.25% KCl (solvent I); to resolve neutral
lipids, the solvent consisted of three parts cyclohexane to two
parts ethyl acetate (solvent II). All solvents were of HPLC
grade and were obtained from Fisher Scientific. To detect C1BODIPY-C12, the plates were scanned on a Bio-Rad Molecular
Image FX scanner equipped with an external laser using filter
sets of 488 nm excitation and 530 nm emission. Positions of the
labeled lipids were compared with those of verified lipid standards (Sigma) resolved on the same TLC plates.

Visualization of C1-BODIPY-C12 uptake into Caco-2 cells
Caco-2 cells were cultured as detailed above on four-well tissue
culture-treated microscope slides (BD Falcon; BD Biosciences);
two wells were used as controls and two wells were used for compound treatment. Treatment of cells with 80 mM perphenazine
for 1 h and uptake of C1-BODIPY-C12 were essentially as detailed
for HTS with the following modifications. After treatment with
compound or MEM (control), medium was removed and cells were
washed with MEM. C1-BODIPY-C12 (final concentration, 5 mM in
5 mM FAF BSA) was added for 3 min without trypan blue. Cells
were then immediately rinsed with MEM, and Elvanol mounting
medium was applied to each well. Cells were imaged using a
Zeiss LSM510 confocal laser scanning microscope (Carl Zeiss
MicroImaging, Inc., Thornwood, NY) equipped with a 633 objective using fluorescence modes. The instrument settings for

brightness and contrast were optimized to ensure that the confocal microscope was set for its full dynamic range relative to untreated cells on the same slide; the same settings were used for
all subsequent image collections. An argon laser source was used
for imaging, with excitation at 488 nm and emission at 505 nm.

Data analysis
Values in arbitrary units of the fluorescent signals from each
HTS plate were exported to Excel (Microsoft Corp., Redmond,
WA) spreadsheet templates, and the assay quality-control Z¶ factor was calculated (46). ChemTree software (Golden Helix, Inc.,
Bozeman, MT) was used for additional statistical analysis and to
study structure-activity relationships.

RESULTS
Library screening
In previous work, we developed a live cell, highthroughput method for the selection of small chemical
modulators of fatty acid uptake dependent upon a mu-

rine FATP expressed in a S. cerevisiae strain deficient in
the long-chain fatty acid transporter Fat1p and the major
ACSL Faa1p (fat1Dfaa1D) (38). In this study, this strain
was used to express the human FATP2 under the control
of the GAL10 promoter. Fatty acid uptake was measured
as an increase in cell-associated fluorescence attributable
to the accretion of the fluorescent fatty acid analog C1BODIPY-C12 through a human FATP2-dependent process. External fluorescence was quenched by the vital dye
trypan blue. We used this system to screen a 2,080 chemical compound library, SpectrumPlus (MicroSource), to select for compounds that altered fatty acid uptake. This
library consists of compounds that are structurally diverse,
including known drugs, experimental actives, and pure
natural products. The collection is advantageous in that
the compounds included have been chosen for diversified
structures containing unique structural scaffolds. Additionally, most compounds included in the set have known
pharmacological and toxicological profiles that can be
used to determine whether the hit compound or structur-

TABLE 1. Compounds that reduced cell-associated fluorescence in humanized yeast
Compound Identifier

01500138
01500184
01500315
01503610
01503253
01503227
01503223
02300061
01500575
01505204
00100325
01503934
01503200
01504079
01503936
01503637
01500127
00310035
00201664
01503207
01505205
01502237
01500473
01500994
01504017
01503239
01500898
01500685
00300038
01504119
0300556
00211118
01500759
01500602
01500510
01500509
01500505
00200022
01504074

Name

Percentage
Transport Inhibitiona

Benzethonium chloride
Chlorpromazine
Gentian violet
Benzalkonium chloride
Methylbenzethonium chloride
Perhexiline maleate
Pararosaniline pamoate
Clomipramine HCl
Thioridazine HCl
Almotriptan
Digitonin
Perphenazine
Centrimonium bromide
Tomatine
Perciazine
Methiothepin maleate
Anthralin
Sanguinarine sulfate
Celastrol
Cyclobenzaprine HCl
Olmesartan medoxomil
Harmol hydrochloride
Phenazopyridine hydrochloride
Flufenazine HCl
Sapindoside A
Hycanthione
Emodin
Clozapine
Juglone
Rhodomyrtoxin B
Chrysarobin
Diacetlydideisovaleryl-rhodomyrtoxin
Quinalizarin
Gossypol
Promethazine
Promazine
Prochlorperazine edisylate
Aklavin HCl
Embelin

100, 100
100, 100
100, 100
100, 100
100, 100
100, 100
100, 100
100, 100
100, 100
100, 100
100, 100
91, 100
100, 96
97, 98
72, 96
59, 100
81, 82
53, 64
75, 97
80, 86
80, 98
89, 83
53, 51
54, 99
75, 92
62, 69
74, 60
66, 50
53, 47
64, 40
34, 42
45, 60
70, 34
40, 44
44, 66
42, 46
45, 47
44, 69
44, 58

Comment

Quenching agent

Quenching agent

Membrane disruptor
Antimicrobial agent

Antibiotic/antifungal agent
Quenching agent

Antifungal agent

Antifungal agent

Quenching agent

a
Percentage inhibition calculated from the ratio of fluorescence in arbitrary fluorescence units (AFU) for cells
with compound compared with positive control cells with 0.8% DMSO alone. Results are from individual samples in
two high-throughput screening trials (trial 1, trial 2).

Screening fatty acid uptake inhibitors

233

excellent consistency between the two experiments. Potential inhibitors were identified using a cutoff value of
3 SD from the mean of the positive and negative controls (Table 1). As expected, most compounds (98%) had
no effect on C1-BODIPY-C12 uptake (Fig. 1). Four compounds enhanced the fluorescence signal, and 39 compounds were identified as potential inhibitors, as they
reduced the cell-associated fluorescence compared with
that of the cells incubated with vehicle alone. Of the
39 compounds, 22 (1.06%) reduced fluorescence by 80–
100% and 17 (0.82%) gave intermediate levels (40–79%
compared with positive controls).

Fig. 1. High-throughput screening for fatty acid transport inhibitors. Cellular accumulation of 4,4-difluoro-5-methyl-4-bora-3a,4adiaza-s-indacene-3-dodecanoic acid (C1-BODIPY-C12) was measured
in arbitrary fluorescence units (AFU) for yeast cells expressing human fatty acid transport protein 2 (FATP2) after incubation with
compounds (diamonds) or with DMSO (triangles; positive control). Accumulation of C1-BODIPY-C12 in cells with empty vector
was used as the negative control (squares). Compounds (80 mM in
0.8% DMSO) or DMSO alone were incubated with yeast cells expressing human FATP2 for 2 h at 30jC before C1-BODIPY-C12 uptake assay. Data points are from one trial.

ally similar compounds can be safely and effectively prescribed for additional medicinal uses.
In our HTS, library compounds were tested at 80 mM
on 384-well plates with yeast cells expressing the human
FATP2. The fatty acid uptake activity of the cells was determined by comparing the cell-associated fluorescence
of cells expressing human FATP2 with that of cells carrying the vector (pDB121) after incubation with the fatty
acid analog C1-BODIPY-C12 (38). The Z¶ factors were calculated from values obtained from positive and negative
controls (two lanes of each per plate) and ranged from
0.61 to 0.80, indicating a robust assay with good discrimination between the positive and negative controls
(47). Two screening trials were performed, and there was

Secondary screens eliminate autofluorescent and
quenching compounds
This primary screening does not distinguish between
effectors that alter apparent fluorescence readings by nonspecific mechanisms, apart from those that interact directly
with FATP. Nonspecific effectors might include those that
increase apparent fluorescence as a result of intrinsic properties specific to the compound or those compounds that
act as quenching agents. Additionally, some compounds
may disrupt membrane integrity and facilitate the internalization of trypan blue, which in turn quenches the
imported fluorescent ligand. Therefore, all compounds
identified as hits in the primary screen were subsequently
tested for autofluoresence, the ability to quench C1-BODIPYC12 fluorescence, and the ability to disrupt membrane integrity (Table 2).
Two compounds identified in the primary screen, acriflavinium hydrochloride and calcein, yielded high intrinsic fluorescence that was not quenched by trypan blue,
suggesting that these compounds did not enhance fatty
acid uptake but increased fluorescence by nonspecific
mechanisms (Fig. 1, Table 2). Sixteen of the 39 compounds that were hits from the primary screening were
colored. These colored compounds might cause an inner filter effect, reducing the fluorescence signal of C1BODIPY-C12 as a result of overlap of their absorption
spectrum with the emission spectrum of the BODIPY fluorophore. To test this concern, we determined the absorp-

TABLE 2. Tests to eliminate compounds with nonspecific effects, including autofluoresence, quenching, and membrane disruption
Compound Identifier

Compound Name

AFU
Compound Alonea

AFU Compound
with C1-BODIPY-C12b

AFU before
Compoundc

AFU after
Compoundd

01500618
01503223
00100325
01503934
Positive controlse
Negative controls f

Acriflavinium chloride
Pararosaniline pamoate
Digitonin
Perphenazine
NR
NR

43,824
100
108
99
NR
NR

60,413
219
28,371
24,628
NR
NR

882
861
802
863
1,092
240

2,821
1,054
420
816
1,145
286

Mechanism

Autofluorescence
Quenching
Membrane disruption
Unknown, potential hit

C1-BODIPY-C12, 4,4-difluoro-5-methyl-4-bora-3a,4a-diaza-s-indacene-3-dodecanoic acid; NR, not relevant.
AFU of 80 mM compound with filter sets of 485 6 20 nm excitation and 528 6 20 nm emission as used to measure cell-associated C1-BODIPY-C12.
b
Average AFU for 5 mM C1-BODIPY-C12 alone was 24,361.
c
Yeast cells expressing human fatty acid transport protein 2 were preloaded with 5 mM C1-BODIPY-C12 under standard assay conditions and
then fluorescence was measured.
d
The same cell samples described in footnote c were incubated with 80 mM compound and incubated for 2 h at 30jC, then fluorescence was
measured again.
e
Yeast cells expressing human FATP2 as described in footnote c with 0.8% DMSO added and no compound.
f
Yeast cells with vector incubated with 0.8% DMSO added and no compound.
a
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tion spectrum of these compounds from 300 to 800 nm
and found two structurally related compounds, gentian
violet (purple) and pararosaniline pamoate (red), that
have absorption maxima at 590 and 550 nm, respectively.
Therefore, they most likely quench C1-BODIPY-C12 fluorescence (emission at 510–625 nm). As expected, when
these compounds were added directly to 5 mM C1-BODIPYC12 in the absence of cells, the fluorescence was reduced significantly (Table 2). These results showed that
both compounds acted as quenching agents to cause
the apparent reduction in cell-associated C1-BODIPY-C12
fluorescence. Another compound, celastrol (orange), also
modestly quenched the BODIPY fluorescence.
Compounds that act as membrane permeants will decrease cell-associated fluorescence because they will allow the vital dye trypan blue to enter the cells. Among
these, the common detergent digitonin (48) is found in
the SpectrumPlus library and was identified by its ability
to reduce fluorescence to background levels. To eliminate
compounds that disrupt membrane integrity, cells were
preloaded with C1-BODIPY-C12 in the presence of trypan
blue for 30 min; each compound was added and cells
were incubated for 2 h, then we revaluated cell-associated
fluorescence. A reduction in fluorescence intensity after
the addition of compound compared with fluorescence
intensity before the addition of compound was interpreted as indicative of a loss of membrane integrity. Among

the 39 compounds, only the cationic detergent digitonin
acted as a strong membrane-permeabilizing agent using
this test (Tables 1, 2). The SpectrumPlus library also contains at least one other cationic detergent, polymixin B
sulfate. This compound weakly inhibited fatty acid uptake
(?30% inhibition compared with positive controls) and
was not included in the selected list of hits from our primary screen. Other compounds with known detergent-like
properties, including centrimonium bromide (described
below), did not affect fluorescence readings of cells preloaded with C1-BODIPY-C12.
Structural analysis of hit compounds in yeast
After eliminating the autofluorescent compounds and
quenching and permeabilizing agents, we compared the
structures of the remaining compounds to identify similar structural cores using ChemTree software. Using a multiple tree clustering algorithm, ChemTree automatically
groups compounds that act according to similar quantitative structure-activity relationship mechanisms. Four groups
of compounds that inhibited C1-BODIPY-C12 uptake were
thus identified as having similar structural scaffolds. Members of the first set are structurally related to the natural
ligands of FATP, fatty acids, in that each has a long aliphatic hydrocarbon chain, including centrimonium bromide and benzalkonium chloride (Table 3). However, the
hydrocarbon chain alone was not sufficient for the inhi-

TABLE 3. Compounds related to fatty acids with aliphatic, hydrocarbon chains
Compound Structure

Compound Name

Percentage
Inhibitiona

Benzalkonium chloride
[ammonium, alkyldimethyl(phenylmethyl)-, chloride]

100, 100

Centrimonium bromide
(hexadecyl-trimethyl-ammonium, bromide)

100, 96

Embelin
(2,5-dihydroxy-3-undecyl-cyclohexa-2,5-diene-1,4-dione)

}

a

44, 57

Batyl alcohol
[3-(octadecyloxy)-1,2-propanediol]

0, 0

Avocadyne
[(2,4-dihydroxyheptadec-16-ynyl) acetate]

0, 0

Percentage inhibition compared with positive controls without compound. Results are for two experiments.
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bition of C1-BODIPY-C12 uptake, because at least five other
compounds with this structural motif in the SpectrumPlus
collection were inactive: batyl alcohol, roccellic acid, vocadyne acetate, avocadyne acetate, and caperatic acid. One
compound, embelin, had intermediate activity. The inactive compounds have the common characteristic of being

highly charged, with multiple hydroxyl groups on the terminal carbon of the chain that may preclude interaction
with the transporter.
The largest number of hits that fell into one structural class was related to the phenazothiazines (Table 4).
Five of these were highly active in preventing uptake,

TABLE 4. Compounds related to phenothiazine
Compound Structure

a
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Compound Name

Percentage Inhibitiona

Chlorpromazine [3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine]

100, 100

Thioridazine HCl [10-(2-(1-methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine]

100, 100

Perphenazine {2-[4-[3-(2-chlorophenothiazin-10-yl)propyl]piperazin-1-yl]ethanol}

91, 100

Flufenazine
[2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl] propyl}piperazin-1-yl)ethanol]

54, 99

Periciazine {10-[3-(4-hydroxy-1-piperidyl)propyl] phenothiazine-2-carbonitrile}

72, 96

Promethazine (N,N-dimethyl-1-phenothiazin-10-yl-propan-2-amine)

45, 47

Promazine (N,N-dimethyl-3-phenothiazin-10-yl-propan-1-amine)

52, 46

Prochlorperazine edisylate
[2-chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine edisylate]

45, 47

Isothiopendyl HCl
[10H-pyrido(3,2-b) (1,4)benzothiazine, 10-(2-(dimethylamino)propyl)-]

0, 0

Triflupromazine
{N,N-dimethyl-3-[2-(trifluoromethyl)phenothiazin-10-yl]propan-1-amine}

0, 0

See Table 3 for details.
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because cell-associated fluorescence remained at background levels. These included perphenazine, perciazine,
chlorpromazine, thioridazine, and flufenazine. Three
derivatives had intermediate activity (promethazine, promazine, and prochlorperazine edisylate) and two were completely inactive (isothiopendyl HCl and triflupromazine).
To further assess the effects of this class of compounds
on fatty acid uptake and metabolism, we compared C1BODIPY-C12 incorporation into lipids of yeast cells expressing human FATP2 treated either with PBS (control)
or with perphenazine (Fig. 2). As expected, C1-BODIPYC12 was incorporated into both phospholipids and neutral
lipids of control cells, and treatment with perphenazine substantially reduced the labeling of essentially all
lipid classes.
A third group of related hit compounds contained a
tricyclic core motif differing from the phenazothiazines
in that the central ring has seven members rather than
six (Table 5). The structures of these compounds are very
similar, and subtle variations contribute to substantial differences in activity. Three compounds strongly inhibited
uptake at 80 mM: clomipramine, methiothepin maleate,

Fig. 2. Perphenazine inhibits the incorporation of the fluorescent
fatty acid analog into various lipids. Lipids were isolated from yeast
cells expressing human FATP2 after treatment with PBS (2) or
perphenazine (1) and C1-BODIPY-C12 as detailed in the text. A:
Solvent system I was used to distinguish phospholipids from
neutral lipids. B: Solvent system II was used to separate neutral
lipids. Images shown are representative of two experiments. TLC
plates were scanned using a phosphorimaging system. Positions
of commercial standards are labeled as follows: NL, neutral lipids;
PE, phosphatidylethanolamine; PS, phosphatidylserine; PC, phosphatidylcholine; TLN, triolean; CE, cholesteryl ester; C, cholesterol.

and cyclobenzaprine. Two were slightly active (clozapine
and imipramine), whereas amitriptyline and loratadine
were inactive.
The final set of compounds, although more structurally diverse within the group, were related in that all were
heterocyclic and highly oxygenated (Table 6). These varied
in the number of rings, from the simplest two-ring compound juglone to the five-ring structure of aklavin.
Toxic compounds are eliminated by evaluating
yeast growth
We previously demonstrated that heat-killed cells
become permeable to the fatty acid analog and the
quenching agent trypan blue, resulting in low fluorescence readings using the C1-BODIPY-C12 assay (38). This
led us to question whether the mechanism of apparent
inhibition of transport was merely attributable to cell
death and associated membrane dysfunction. To test
compound toxicity, wild-type yeast cells (YB332) were
grown in YPDA to mid-log phase and then diluted to
0.1 OD600. Serial dilutions of a test compound were added
to medium, and growth of the yeast cells was monitored
relative to cells incubated without the addition of
compound. Figure 3 shows the growth curves of YB332
in the presence of PBS (control) or 100 mM centrimonium bromide, anthralin, or perphenazine. At 100
mM, perphenazine seemed to inhibit the growth of yeast
cells. Therefore, we further tested the viability of yeast
cells in the presence of this putative inhibitory compound
by plating cells on solid medium after treatment with
compound for 2 h to mimic the conditions used in our
HTS experiments. Using this method, .95% of the cells
were viable. Therefore, we do not believe that inhibition
by perphenazine was merely the result of cell death.
Evaluation of hit compounds in Caco-2 cells
Caco-2 cells are derived from a human colon adenocarcinoma (49). In culture, these cells spontaneously
differentiate into polarized, columnar cells that are representative of the small intestine (50). When grown on
plastic, they form domes typical of normal and transporting epithelium (51, 52). This cell line has been used
extensively as a model for transport studies (50, 53).
Previous work has shown that fatty acid uptake in Caco-2
cells is saturable, decreased by trypsin treatment of cells,
and can be competed by natural fatty acids (54). These
cells express higher levels of both FATP2 and FATP4
than other FATP isoforms (P. N. Black, P. Fraisl, and
C. C. DiRusso, unpublished data). To further evaluate
hit compounds identified from our screening of yeast
cells, we performed C1-BODIPY-C12 uptake inhibition
experiments in 96-well format using Caco-2 cells. We
initially tested the hit compounds in Caco-2 cells at 100
and 10 mM (Table 7). At 100 mM, most of these compounds inhibited Caco-2 uptake of C1-BODIPY-C12 to
varying extents. Seven compounds reduced uptake to essentially control levels, whereas most had intermediate
activity. When the concentration of compound was deScreening fatty acid uptake inhibitors
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TABLE 5. Compounds related to cyclobenzaprine
Compound Structure

Compound Name

Clomipramine
[3-chloro-5-(3-(dimethylamino)propyl)-10,11-dihydro-5H-dibenz(b,f)azepine]

a

100, 100

Methiothepin maleate
[(12)-1-(10,11-dihydro-8-(methylthio)dibenzo(b,f )thiepin-10-yl)-4-methylpiperazine]

59, 100

Cyclobenzaprine [1-propanamine, 3-(5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl- (9CI)]

80, 86

Clozapine [8-chloro-11-(4-methyl-1-piperazinyl)-5H-dibenzo(b,e) (1,4)diazepine]

66, 50

Imipramine [1-(3-dimethylaminopropyl)-4,5-dihydro-2,3,6,7-dibenzazepine]

0, 26

Amitriptyline HCl [10,11-dihydro-5-(g-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene]

0, 0

Loratadine [ethyl 4-(8-chloro-5,6-dihydro11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylate]

0, 0

See Table 3 for details.

creased to 10 mM, only three compounds inhibited uptake
by 25–40% of control levels (Table 7).
We next evaluated the concentration-dependent inhibition of centrimonium bromide, perphenazine, and anthralin on Caco-2 cells by comparison with yeast (Fig. 4).
The results shown in Fig. 4B indicate that the Ki values
of centrimonium bromide and perphenazine for Caco-2
cells was higher than that of yeast cells (Fig. 4A). For
anthralin, we were unable to determine the Ki in Caco-2
238

Percentage
Inhibitiona

Journal of Lipid Research

Volume 49, 2008

cells, because at 200 mM the uptake was still ?70% of the
control value. As was the case in yeast, C1-BODIPY-C12 was
incorporated into Caco-2 cells, labeled various cellular
lipids, and did not show preferential compartmentalization (Fig. 5). Treatment with a representative compound,
perphenazine, substantially reduced incorporation without causing cell death; at 80 mM perphenazine, there was
94 6 9% cell survival, as estimated using the MTT cytotoxicity assay (five experiments).

TABLE 6. Compounds related to anthralin
Compound Structure

Percentage Inhibitiona

Compound Name

Anthralin (1,8,9-trihydroxyanthracene)

81, 82

Emodin (1,3,8-trihydroxy-6-methyl-9,10-anthracenedione)

74, 60

Juglone (5-hydroxy-1,4-naphthoquinone)

53, 47

Chrysarobin (6-methylanthracene-1,2,8-triol)

34, 42

Quinazalin (1,2,5,8-tetrahydroxyanthracene-9,10-dione)

70, 34

Rutilantinone
[1-naphthacenecarboxylic acid, 1,2,3,4,6,11-hexahydro-2-ethyl2,4,5,7,10-pentahydroxy-6,11-dioxo-, methyl ester, (1R,2R,4S)-]

a

3, 54

Aklavin
[methyl (1S,2S)-4-(4-dimethylamino-5-hydroxy-6-methyl-oxan-2-yl)oxy-2ethyl-2,5,7-trihydroxy-6,11-dioxo-3,4-dihydro-1H-tetracene-1carboxylate hydrochloride]

44, 69

Mitoxanthrone
[1,4-dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)9,10-anthracenedione]

19, 39

See Table 3 for details.

DISCUSSION
Validation of the screening method
In this study, we tested a HTS system for use in identifying fatty acid uptake inhibitors. The target of this HTS,

the human fatty acid uptake system, is likely to be involved
in the development and progression of many disease states
that result from excessive intracellular accumulation of
free fatty acids. We chose to use S. cerevisiae cells expressing the human FATPs for our primary screening because
Screening fatty acid uptake inhibitors

239

3) yeast cells are small in size, grow rapidly, and are resistant to cell lysis upon automated manipulation; and 4)
the yeast HTS system is simple and inexpensive to implement. Our strategy was to carry out the HTS and initial
screening for lead compounds using the humanized yeast
system and then to analyze these compounds for their inhibition of fatty acid uptake in human cells. We validated
this approach by screening a 2,080 compound library and
identifying groups of compounds with similar chemical
structures that inhibited fatty acid uptake in both yeast
cells and human Caco-2 cells.

Fig. 3. Growth of yeast in the presence of selected hit compounds.
Wild-type yeast was cultured in the presence of 100 mM compound
as indicated; cells with an equivalent volume of 0.8% DMSO in PBS
were included as a control. Growth was monitored at optical density
at 600 nm over 8 h as shown. CTAB, centrimonium bromide.

1) the biochemistry and molecular genetics of fatty acid
uptake in yeast are well understood and analogous to
those of mammalian cell systems; 2) phenotypic tests for
fatty acid uptake and metabolism are readily available;

Hit compounds similar in structure to long-chain
fatty acids
BODIPY-labeled fatty acids have been used to monitor
fatty acid uptake (22, 26, 27) and have been shown to
be biosynthetically incorporated into lipids of cells (55;
this work) and cultured organs (56). The length of C1BODIPY-C12 is approximately equivalent to that of an 18carbon fatty acid. Our laboratory also demonstrated that
the uptake of this fluorescent fatty acid analog is effectively competed by the natural fatty acid oleate in yeast (38).
In the present study, of 2,080 compounds screened, four
groups of structurally related compounds were identified
as hits as a result of inhibition of C1-BODIPY-C12 uptake.
Among these were two ionic detergents, centrimonium bro-

TABLE 7. Inhibition of fatty acid uptake in Caco-2 cells by compounds identified using humanized yeast
Percentage Inhibitiona
(Experiment 1, Experiment 2)

Identifier

Compound Name

100 mM

10 mM

01500138
01500184
01500315
01503610
01503253
01503227
01503223
02300061
01500575
01505204
00100325
01503934
01503200
01504079
01503936
01503637
01500127
00310035
00201664
01503207
01505205
01502237
01500473
01500994
01504017
01503239
01500898
00300038
01504119
0300556
00211118
01500602

Benzethonium chloride
Chlorpromazine
Gentian violet
Benzalkonium chloride
Methylbenzethonium chloride
Perhexiline maleate
Pararosaniline pamoate
Clomipramine HCl
Thioridazine HCl
Almotriptan
Digitonin
Perphenazine
Centrimonium bromide
Tomatine
Perciazine
Methiothepin maleate
Anthralin
Sanguinarine sulfate
Celastrol
Cyclobenzaprine HCl
Olmesartan medoxomil
Harmol hydrochloride
Phenazopyridine hydrochloride
Flufenazine HCl
Sapindoside A
Hycanthione
Emodin
Juglone
Rhodomyrtoxin B
Chrysarobin
Diacetlydideisovaleryl-rhodomyrtoxin
Gossypol

91, 96
43, 68
95, 98
88, 94
90, 95
95, 98
57, 76
27, 58
42, 67
10, 49
79, 97
53, 74
39, 65
85, 92
11, 49
11, 50
0, 42
30, 60
77, 88
2, 44
7, 47
10, 48
73, 87
41, 67
92, 63
38, 65
62, 79
9, 48
44, 68
17, 53
46, 69
72, 80

14, 14
9, 9
52, 53
7, 8
52, 53
9, 9
14, 14
5, 5
12, 12
10, 10
18, 18
14, 14
15, 15
9, 10
9, 8
6, 5
15, 16
13, 13
19, 19
15, 15
18, 18
6, 6
40, 41
14, 15
0, 0
16, 15
31, 31
0, 0
15, 15
11, 11
19, 19
23, 24

a

Comment

Quenching agent

Quenching agent

Membrane disruptor
Antimicrobial agent

Quenching agent

Quenching agent

Percentage inhibition calculated from the ratio of fluorescence in AFU for cells with compound compared with positive control cells with
DMSO alone. Results given are averages of triplicate samples for each of two experiments.
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Fig. 4. Concentration dependence of the inhibition of uptake by centrimonium bromide (CTAB), perphenazine, and anthralin. The 100%
of control values indicates values for cells incubated with PBS (yeast) or Hanks’ balanced salt solution (Caco-2). A: Yeast cells expressing
human FATP2 were incubated with compounds at 30jC for 2 h before uptake assay. B: Caco-2 cells were incubated with different
concentrations of the compounds at 37jC for 1 h before uptake assay. * Anthralin at 200 mM kills Caco-2 cells. Data points are means of three
experiments assayed in triplicate. Error bars indicate SEM. Ki, inhibition constant.

mide and benzalkonium chloride, which are similar to fatty
acids in having a long hydrocarbon chain. These compounds may act as nonspecific detergents or may mimic fatty
acids by interacting with FATP specifically, for example, by

occupying the fatty acid binding site on the protein. We
noted that these two compounds have critical micelle concentrations in the same range as cholic acid and deoxylcholic acid (1–4 mM), which did not reduce apparent

Fig. 5. Perphenazine blocks the incorporation of C1BODIPY-C12 into Caco-2 cells. Caco-2 cells were treated
for 1 h with vehicle (MEM) alone (A) or 80 mM perphenazine followed by C1-BODIPY-C12 for 3 min (B). Cells
were imaged under fluorescence using confocal microscopy as detailed in the text.

Screening fatty acid uptake inhibitors

241

fatty acid uptake, so nonspecific detergent effects do not
adequately explain the inhibition of uptake by centrimonium bromide and benzalkonium chloride. Filipin, nystatin,
and b-escin, three other compounds that disrupt cell wall
and/or membrane architecture, also had no effect on uptake in our primary screening assay. Therefore, at the concentration used in these experiments (80 mM), it does not
appear that these compounds disrupt FATP2-mediated fatty
acid transport by nonspecific actions.
Some atypical antipsychotic drugs also inhibit uptake
The other two groups of compounds all have a three-ring
structure similar to the BODIPY moiety of C1-BODIPY-C12
(Tables 4, 5). One concern is that these compounds are
merely competitive inhibitors of the fluorescent fatty acid
analog and not the natural ligands. However, this is most
likely not the case, because C1-BODIPY-C12 is taken up in
a FATP-specific manner and can be metabolized upon
import. Furthermore, the native ligand (oleate) effectively
competes with C1-BODIPY-C12 (38). Thus, it is presumed
the fluorescent ligand binds to the transporter in a manner analogous to the natural ligand. Compounds identified in this screen within these two structural classes fall
into a family with well-known pharmacological properties
that include antipsychotic drugs, which act by inhibition
of neuroreceptors, including the dopamine receptor
(39). Hints at a role for these compounds in fatty acid
and lipid metabolism come from studies showing that
these compounds are associated with hypertriglyceridemia, cholestatic liver, and insulin resistance (57, 58). A
recent gene expression array study demonstrated a
correlation between alterations in gene expression resulting from treatment of cells in culture with phenothiazine drugs and expression changes induced by
treatment of cells with arachidonic acid (59). Together,
these data strongly suggest that these drugs may affect
lipid homeostasis in whole or in part through the inhibition of fatty acid uptake into cells. On the other hand,
although these adverse side effects might seem to eliminate this class of compounds from consideration as
potential fatty acid uptake inhibitors, they may prove
useful in other ways. First, they will be valuable to
understand the mechanisms causing the unwanted side
effects of the drugs now in clinical use. Second, they
potentially could be modified/rationally designed to
interact more specifically with neuroreceptors rather
than the FATP proteins and visa versa. Third, they are
expected to be informative regarding mechanisms of
FATP activity.
Few antifungal drugs in the library altered
transport activity
Several compounds identified as hits were the antifungal agents tomatine, juglone, and sapinoside A. These
compounds might act by killing the cell or inhibiting metabolic processes, including uptake. Because our primary
screening assay requires only a 2 h incubation period with
the compound, and because the addition of compound before C1-BODIPY-C12 uptake did not result in reduced cell242
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associated fluorescence, we do not believe that these
compounds are merely killing the cells. Cell death also results in increased membrane permeability. Metabolic poisoning might have the same effect in reducing membrane
function, but this mechanism is more difficult to disprove
with the types of assays available. We also note that the
SpectrumPlus collection contains numerous antifungal
agents that had no effect on C1-BODIPY-C12 uptake by
our method. Among these were fluconazole, griseofluvan,
and clotrimazole.
In summary, we have designed multiple systems to identify and evaluate fatty acid uptake inhibitors. Primary
screening and initial specificity evaluation used yeast cells
that express a human FATP family member. Secondary
screening has been developed in human cells (Caco-2)
to verify and further evaluate the specificity of the lead
compounds for inhibition of fatty acid uptake. This uptake assay has some aspects in common with another
assay recently reported by Liao et al. (60). However, our
method differs in that any cell type (from yeast to human
cells) can be used with a high degree of sensitivity and
reproducibility using an inexpensive quenching agent.
In the future, we hope to use this method to identify
compounds that discriminate between different classes of
fatty acids or different FATP family members. Apart from
identifying fatty acid uptake inhibitors, this system will
also be of value in identifying fatty acid uptake activators.
Additionally, although we have targeted human FATPmediated fatty acid uptake in genetically defined yeast,
modifications could be made in this system to target
other participants in fatty acid transport, metabolism,
and trafficking operative in living cells. Another anticipated use of this screening system is in determining
whether or not lead drugs interfere with fatty acid uptake and metabolism before they enter whole animal or
human trials. In this regard, this inexpensive, rapid, live
cell assay should prove an adaptable secondary screen for
this purpose.
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